Why It Could Be The Perfect Time To Buy Rolls-Royce Holding PLC And GlaxoSmithKline plc

Why now could be the time to buy Rolls-Royce Holding PLC (LON: RR) and GlaxoSmithKline plc (LON: GSK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The market’s recent declines have thrown up some great bargains. 

Rolls-Royce (LSE: RR) and GlaxoSmithKline (LSE: GSK) were already cheap before the sell-off began earlier in the year. But recent declines have only depressed their valuations and now they look more attractive than they have done for several years on a number of metrics. 

Dividend concerns 

Rolls’ shares plunged to a new five-year low this week as shareholders brace themselves for the company’s first dividend cut in 24 years when the aero-engine maker reports annual results on Friday. Management warned back in November that the payout was under review, and City analysts are expecting a 30% cut as the group seeks to strengthen its balance sheet after five profit warnings in the past two years. What’s more, there have been concerns that Rolls will announce a sixth profit warning this Friday when the company reports its results for 2015. 

However, Rolls’ long-term outlook is more positive. For example, US hedge fund ValueAct Capital, which has taken a stake in Rolls, believes that the company’s aerospace earnings could grow by as much as 20% per annum through 2020 as orders are filled and new engines developed. Aerospace accounts for 80% of Rolls’ earnings before interest and tax. Cutting costs, using excess capacity and ramping up production, are what ValueAct believes will make Rolls’ earnings grow strongly over the next four years. 

Rolls’ management has promised to bring down costs by up to £200m from 2017, on top of a planned £115m reduction, in an attempt to boost profitability and cash generation.

That said, at present levels Rolls’ shares trade at a year-end 2016 P/E of 20.5 according to analysts’ predictions, which doesn’t leave much room for error if things don’t go to plan. With that being the case, Rolls might not be suitable for risk-averse investors. 

Ahead of target

At the beginning of February, Glaxo announced its full-year results for 2015, which met expectations. Sales rose 4% to £23.9bn while core net profits, which exclude some exceptional items, were £3.7bn, or 75.7p a share. 

Alongside the results, Glaxo also announced that it was on course to meet its target for earnings to increase by a double-digit percentage this year as rising sales from new products begin to outweigh declines in the company’s best-selling Advair asthma drug. Moreover, the company estimates that it will now generate £6bn in annual sales from new medicines two years ahead of target. 

Unfortunately, it seems as if the market has just ignored these results from Glaxo. Since the announcement, the company’s shares have fallen by 6.3%, but this could offer an excellent opportunity for long-term investors. 

Indeed, Glaxo’s outlook is now more attractive than it has been for a long time. The company is set to return to growth this year, and the dividend yield of 5.9% is safe for the time being. Glaxo’s shares currently trade at a forward P/E of 15.8. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline and Rolls-Royce. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »